Phenylglycinamide derivatives useful as anticoagulants

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S146000

Reexamination Certificate

active

07622585

ABSTRACT:
The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it0 is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

REFERENCES:
patent: 5023236 (1991-06-01), Edgington et al.
patent: 5475106 (1995-12-01), Bourzat et al.
patent: 5602101 (1997-02-01), Schacht et al.
patent: 5843442 (1998-12-01), Soule et al.
patent: 5866542 (1999-02-01), Vlasuk et al.
patent: 6140353 (2000-10-01), Ackermann et al.
patent: 6194409 (2001-02-01), van Boeckel et al.
patent: 6242644 (2001-06-01), Ackermann et al.
patent: 6335324 (2002-01-01), Bisacchi et al.
patent: 6358960 (2002-03-01), Senokuchi et al.
patent: 6472393 (2002-10-01), Aliagas-Martin et al.
patent: 6642252 (2003-11-01), Bisacchi et al.
patent: 6699994 (2004-03-01), Babu et al.
patent: 6900207 (2005-05-01), Ohmoto et al.
patent: 2003/0166694 (2003-09-01), Dorsch et al.
patent: 2004/0176375 (2004-09-01), Bisacchi et al.
patent: 2004/0204412 (2004-10-01), Glunz et al.
patent: 2005/0107409 (2005-05-01), Priepke et al.
patent: 2006/0211720 (2006-09-01), Glunz et al.
patent: 2007/0003539 (2007-01-01), Zhang et al.
patent: 10310278 (2004-09-01), None
patent: WO 96/20689 (1996-07-01), None
patent: WO 97/10214 (1997-03-01), None
patent: WO 01/44172 (2001-06-01), None
patent: WO 01/90051 (2001-11-01), None
patent: WO 02/09688 (2002-02-01), None
patent: WO 02/34711 (2002-05-01), None
patent: WO 03/013531 (2003-02-01), None
patent: WO 03/066588 (2003-08-01), None
patent: WO 03/084533 (2003-10-01), None
patent: WO 2004/072101 (2004-08-01), None
patent: WO 2005/054430 (2005-06-01), None
Carson, S.D. et al., “The role of tissue factor in the production of thrombin”, Blood Coagulation and Fibrinolysis, vol. 4, pp. 281-292 (1993).
Colman, R.W., Chapter 6: “Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities”, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 103-121 (2001).
Girard, T.J. et al., “The role of tissue factor/factor Vlla in the pathophysiology of acute thrombotic formation”, Current Opinion in Pharmacology, vol. 1, pp. 159-163 (2001).
Goodnight, S.H. et al., Chapter 4: “Screening Tests of Hemostasis”, Disorders of Hemostasis and Thrombosis: A Clinical Guide, The McGraw-Hill Companies, publ., pp. 41-51 (2001).
Schmaier, A.H., Chapter 5: “Contact Activation”, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 105-127 (2001).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Phenylglycinamide derivatives useful as anticoagulants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenylglycinamide derivatives useful as anticoagulants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylglycinamide derivatives useful as anticoagulants will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4130259

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.